Inactivated Poliomyelitis Vaccine Made From Sabin Strain (Vero Cells)

Product Advantages:

The first single-dose inactivated poliomyelitis vaccine all over the world
Attenuated strain + Inactivated virus = double lock
High cross-neutralization property is proved by the CDC of US
Introduced to the Global Polio Eradication & Endgame Strategic Plan by WHO

Inactivated Poliomyelitis Vaccine Made From Sabin Strain (Vero Cells)
About Products Product Description R & D process Publications Related news

The First Inactivated Poliomyelitis Vaccine Made from Sabin Strains (Sabin IPV)All Over the World.


30 years tackling and the joint efforts from three-generation researchers fruited the first IPV made from Sabin strains. 

Both the Sabin strain viruses and Vero cell substrates used in manufacturing are provided by WHO.

Microcarrier suspension bioreactor cultivation system is utilized in production, whose scale is the largest in China to date.

Down-stream processing purification technology promises a high purity of Sabin IPV.   


The Best Weapon for Human to Eradicate Poliomyelitis.


As an inactivated vaccine, it is safe for children, because it cannot cause paralysis. 

The use of attenuated Sabin strain instead of wild-type Salk strain to make IPV is much safer to manufacturers, as Sabin IPV is a vaccine made from a vaccine. 

From phase Ⅱ production base, IMBCAMS will provide Sabin IPV, the best weapon in eradicating polio, to all the children both in China and worldwide.

Main Active Composition:

Inactivated Attenuated Poliovirus Strain

Type (Sabin)………………30DU

Type (Sabin)………………32DU

Type (Pfizer)………………45DU

Description: Orange or saffron liquid, clear, transparent, no visible impurity.

Storage: Stored and transported in 2-8 and protected from light. Avoid freeze.

Period of Validity: 24 months.

Packaging: Vials. Each small box has one vial of IPV containing 1 dose or 5 doses.


The vaccine is indicated for active immunization of infants and children for the prevention of poliomyelitis caused by poliovirus Type 1, 2 and 3.


Infants and children, mainly from the age of 2 months onwards (including 2 months).

Administration and Dosage

The primary immunization should be administered intramuscularly at 2, 3, 4 months age; and a booster dose of the vaccine is administered intramuscularly at 18 months; or follow the national immunization program. For infants, the center of anterolateral thigh is the preferred site, and deltoid muscle of upper arm is the idea area for children.


    Coming Soon...